Bioactive Peptide-Based Probes by Hicks, Clair D. & Crooks, Peter A.
University of Kentucky
UKnowledge
Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences
7-20-2010
Bioactive Peptide-Based Probes
Clair D. Hicks
University of Kentucky, clhicks@uky.edu
Peter A. Crooks
University of Kentucky
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in
Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Recommended Citation
Hicks, Clair D. and Crooks, Peter A., "Bioactive Peptide-Based Probes" (2010). Pharmaceutical Sciences Faculty Patents. 42.
https://uknowledge.uky.edu/ps_patents/42
(12) United States Patent 
Hicks et a]. 
US007759468B1 
US 7,759,468 B1 
Jul. 20, 2010 
(10) Patent N0.: 
(45) Date of Patent: 
(54) BIOACTIVE PEPTIDE-BASED PROBES 
(75) Inventors: Clair L. Hicks, Nicholasville, KY (US); 
Peter Anthony Crooks, Nicholasville, 
KY (US) 
(73) Assignee: University of Kentucky Research 
Foundation, Lexington, KY (U S) 
( * ) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 814 days. 
(21) Appl.No.:10/795,174 
(22) Filed: Mar. 5, 2004 
Related US. Application Data 
(60) Provisional application No. 60/452,122, ?led on Mar. 
5,2003. 
(51) Int. Cl. 
C07K 1/00 (2006.01) 
(52) US. Cl. ..................... .. 530/402; 530/345; 530/409; 
530/410 
(58) Field of Classi?cation Search ..................... .. None 
See application ?le for complete search history. 
(56) References Cited 
U.S. PATENT DOCUMENTS 
5,106,762 A * 4/1992 Bredehorst et a1. ........ .. 436/546 
5,612,182 A * 3/1997 Pearson et al. .. .... .. 435/6 
6,218,160 B1* 4/2001 Duan ....................... .. 435/188 
6,416,758 B1* 7/2002 Thorpe et al. .......... .. 424/1451 
6,440,419 B1* 8/2002 Hein et al. 424/1781 
2004/0121403 A1* 6/2004 Miller ...................... .. 435/7.1 
FOREIGN PATENT DOCUMENTS 
WO 02/061117 * 8/2002 
OTHER PUBLICATIONS 
Jarvis et al (Int. Dairy Journal, 5:963-976, 1995).* 
Messeri et al, Journal of Bioluminescence and Chemiluminescence, 
4:154-158, 1989* 
Wood et a1, Methods in Enzymology, 133:354-365, 1986* 
Surjawan et al. Inhibition of Lactococcus lactis ssp. lactis c2 
bacteriophage proliferation in L. lactis ssp lactis c2 grown in medium 
containing heat treaetedL. lactis ssp. lactis c2 phage-peptide. J. Dairy 
Sci. 83 (Suppl. 1): 92 (Abst. 395). 2000. 
Surjawan et al. Inhibition of Lactobacillus plantarum yit 0068 
bacteriophage proliferation in L. plantarum host grown in medium 
containingLactococcus lactis ssp. lactis c2 phage peptide. Inst. Food 
Technol. Annual Meeting Book of Abstracts. (Abst. 65C-8) pp. 147. 
2000. 
Jose et al. Inhibition of Lactobacillus plantarum yit 0068 bacterioph 
age proliferation in L. plantarum host grown in medium containing L. 
plantarum yit 0068 phage peptide. Inst. Food Technol. Annual Meet 
ing Book ofAbstracts. (Abst. 65C-10) pp. 147. 2000. 
Hicks et al. Effect of 02 phage peptides on Lactococcus lactis ssp. 
lactis c2 agglutination. J. Dairy Science 82 (Suppl. 1) :10. 1999. 
Hicks et al. Development of bioactive probes derived from 
bacteriophage. 1 st Annual KY Innovation and Enterprise Conference 
Proc., Mar. 4, 2003. 
Hicks et al. Use of HydroliZed Whey peptide to inhibit culture agglu 
tination. J. dairy Sci 83. 2000. pp. 1196-1202. 
* cited by examiner 
Primary ExamineriPatricia A Duffy 
(74) Attorney, Agent, or FirmiKing & Schickli, PLLC 
(57) ABSTRACT 
A method for preparing a site-speci?c peptide probe, wherein 
the peptide is speci?c to a receptor, includes modifying a 
marker to include a tether molecule and covalently binding 
the tether molecule to the peptide. The present invention also 
provides a labeled probe, comprising a peptide speci?c for a 
receptor and a marker. The marker is modi?ed to include a 
tether molecule capable of covalently binding to the peptide. 
The peptide is typically derived from a bacteriophage or is a 
synthetic analog or derivative of the peptide. The receptor will 
typically be found on a surface of a bacterial cell. The method 
and probe of the invention are suitable for a rapid assay for a 
bacteria in a complex mixture. 
12 Claims, 2 Drawing Sheets 
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BIOACTIVE PEPTIDE-BASED PROBES 
This application claims the bene?t of US. Provisional 
Patent Application Ser. No. 60/452,122, ?led Mar. 5, 2003. 
TECHNICAL FIELD 
The present invention relates to marker systems utilizing 
peptides. Inparticular, the invention relates to use of bioactive 
peptide probes labeled With desired marker molecules. The 
probes are useful in a number of assays, for example as part of 
a rapid cell detection system. The peptides are speci?c to 
receptors on bacterial cells, and may be derived from hydroly 
sis of bacteriophage cells or synthetic analogs or derivatives 
thereof. 
BACKGROUND OF THE INVENTION 
Many neW rapid assays for microorganisms have been 
developed during the last decade. For example, tWo of the 
most sensitive tests on the commercial market are based on 
nucleic acid probes and the Polymerase Chain Reaction 
(PCR) assay. Most other tests such as radioimmunoassay and 
ELISA require signi?cantly higher levels of speci?c bacteria 
for enumeration. Thus, When samples With loW counts are 
assayed by RIA or ELISA, an enrichment step is necessary. 
Nucleic acid probes consist of DNA sequences from a 
target bacteria that are used to detect homologous sequences 
of bacterial DNA or RNA. Generally, the DNA of the probe 
contains a radioisotope (e.g. 32P, 3H, 125I, or 14C) or other 
reporter molecule. When the probe DNA hybridizes With the 
bacterial DNA/RNA, hybridization can be detected. Detec 
tion limits can be as loW as 104 cfu/g, but are best When 
detecting 106 to 107 cfu/ g. Nucleic acid probe based methods 
are problematic in the limited number of probes, the sample 
preparation time, enrichment time, and the complexity of the 
process. Thus this detection method has not been utilized by 
commercial industries or medical laboratories. 
PCR techniques more suited to identi?cation of microor 
ganisms rather than enumeration, but detection limits may be 
as loW as a single cell in puri?ed media even in a mixed 
bacterial cell population. HoWever, some compounds impede 
the ampli?cation process of PCR techniques and limit the 
sensitivity to greater than 104 cfu/ml. For example, PCR 
hybridization has been reported to be impeded in the presence 
of fermented solids such a cheese or Whey. Also, many PCR 
assays require a 12 hour or overnight pre-enrichment step 
plus the time for hybridization. The complexity of the hybrid 
ization step tends to limit the procedure to a sophisticated 
facility such as a research laboratory. Thus the process time 
and complexity of the process limits the use of this procedure 
by many industrial and medical laboratories. 
Factors that affect the commercial use of a rapid assay 
include: dif?culty of sample preparation, time required to 
enrich the bacteria in question, sensitivity of the assay, time 
required to complete the assay, and cost. Most food and 
medical rapid assays are limited by the sample preparation 
time and the assays sensitivity in a “dirty” system (i.e., a 
system such as a ?uid containing solids or slight turbidity). 
Therefore, there is a need in the art for a rapid assay for 
microorganisms for use in a relatively “dirty” system. The 
rapid assay should have the features of high sensitivity and 
loW preparation and assay time. 
Many viruses or bacteriophages have been studied, char 
acterized, and used to develop commercial antiviral products. 
Fluorescent reporters or markers have been bound to bacte 
riophages as an assay for host bacterial organisms. HoWever, 
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the saturation of the dye or marker on the surface of the 
bacteriophage and the number of bacteriophage that bind 
With the host cell is variable. Accordingly, the use of bacte 
riophages to deliver a marker to a host cell for rapid assay 
purposes has not been extensively commercialized. 
It is knoWn to use peptides derived from bacteriophages in 
a variety of useful applications. For example, US. Pat. No. 
6,297,042 for CHEESE MAKING WITH BACTERIOPH 
AGE RESISTANT BACTERIA, incorporated herein by ref 
erence, describes a method for reducing bacteriophage attack 
on bacteria used in the cheese making industry. The method of 
the ’042 patent comprises addition of “blocker” peptides 
derived by enzymatic treatment of immunoglobulins, bacte 
riophages, bacteriophage parts, or mixtures thereof. Simi 
larly, peptides derived by hydrolysis of Whey proteins have 
been used to inhibit culture agglutination (clumping and 
chaining of cells) (Ustunol, Z. and C. L. Hicks. 1994. Use of 
an enzyme-treated, Whey-based medium to reduce culture 
agglutination. J. Dairy Sci. 77:1479-1486; Hicks, C. L., C. E. 
Onuorah, and I. SurjaWan. 2000. Use of hydrolyzed Whey 
peptides to inhibit culture agglutination. J. Dairy Sci. 
83: 1196-1202; both incorporated herein by reference), pre 
vent binding of intact immunoglobulins (Hicks, C. L. and Z. 
Tabeidie. 1998. Effect of homogenization on immunoglobu 
lins’ agglutination response in presence of lactic cultures. J. 
Dairy Sci. 81(Suppl. 1):32; Tabeidie, Z. and C. L. Hicks. 
1998. Effect of heat treatment on immunoglobulins’ aggluti 
nation response in presence of lactic cultures. J. Dairy Sci. 
8 1 (Suppl. 1):32; both incorporated herein by reference), and 
block bacteriophage adsorption and inhibit bacteriophage 
proliferation (Hicks, C. L., C. E. Onuorah, andI SurjaWan. 
2002. Use of hydrolyzed Whey peptides to inhibit Lactococ 
cus laclis ssp. cremoris WWa phage proliferation. J. Dairy Sci. 
84:Submitted; US. Pat. No. 6,297,042; both incorporated 
herein by reference). Peptides derived from ?cin hydrolysis 
of bacteriophage (q)c2) Were shoWn to inhibit groWth of Lac 
lococcus laclis ssp. laclis C2 (Hicks, C. L., P. A. Clark-Safko, 
I. SurjaWan, and J. O'Leary. 2004. Use of bacteriophage 
derived peptides to delay phage infections. Food Res. Intl. 37 
(2)11 15-122; incorporated herein by reference). 
The present invention addresses the identi?ed need in the 
art by providing bioactive probes comprising peptides labeled 
With a marker. Typically, the peptides are attachment peptides 
derived from bacteriophages, or are synthesized analogs or 
derivatives Which correspond to such attachment peptides 
and to bind to the same receptor molecules. It is knoWn that 
attachment peptides of various bacteriophages can range 
across genus (i.e. peptide sequences that bind to calcium 
receptors), or can be limited to individual strains (i.e. peptide 
sequences speci?c to multiple carbohydrate moieties of a 
particular bacterial cell Wall). Thus, peptide-based probes are 
provided, attached to a marker, Which deliver the marker to 
the surface of a speci?cally targeted bacteria Where the con 
centration of the marker can be quanti?ed. Further, a method 
for detecting a bacteria is provided, comprising attaching a 
detectable molecule to a smaller bacteriophage peptide or 
synthetic bacteriophage peptide Which binds to speci?c host 
bacteria, thereby increasing saturation of the marker and 
improving sensitivity of the assay. 
SUMMARY OF THE INVENTION 
In accordance With the purposes of the present invention as 
described herein, a method is provided for preparing a site 
speci?c peptide probe, comprising modifying a marker to 
include a tether molecule, Wherein the peptide is speci?c to a 
receptor and the tether molecule is capable of covalently 
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binding to the peptide, and covalently binding the tether mol 
ecule to the peptide. The tether molecule may be adapted to 
covalently bind to the primary amine or to the carboxyl end of 
the peptide. Typically, the receptor Will be found on a surface 
of a bacterial cell, such as for example the F protein receptor. 
The peptide may include an N terminal sequence ( . . . Ala 
Glu-Leu-Glu, SEQ ID NO: 1;Ala-Lys-Glu-Lys-Tyr-Val-Ile 
Gln-Ala-Glu-Leu-Glu, SEQ ID NO: 3) or a calcium binding 
sequence (Ser-Asn-Glu-Glu-Met . . . ; SEQ ID NO: 2) of the 
F protein. 
The peptide may be produced by hydrolysis of a bacte 
riophage. The bacteriophage may be selected from the group 
of bacteriophages speci?cally binding to Laclobacillus, Lac 
Zococcus, Salmonella, Escherichia, and mixtures thereof. The 
bacteriophage may be selected from the group of bacterioph 
ages speci?cally binding to Laclobacillusplanlarum species, 
Laclococcus laclis species, Salmonella zyphimurium species, 
Salmonella choleraesuis species, Escherichia coli species, 
and mixtures thereof. 
In one embodiment, the peptide is derived by hydrolyZing 
a bacteriophage With a protease enZyme. The protease may be 
selected from a group consisting of papain, bromelain, ?cin, 
pepsin, trypsin, chymotrypsin, and mixtures thereof. In 
another embodiment, the peptide may be a synthetic analog or 
derivative of a bacteriophage peptide. Still further, the peptide 
may be Lys-Lys-Lys, Glu-Glu, or a mixture thereof. 
The marker may be selected from the group consisting of a 
luciferin compound, a luminol compound, and mixtures 
thereof, the luciferin compound and luminol compound being 
modi?ed to include a tether molecule. In one embodiment, 
the marker is 6-[carboxymethoxyacetyl-N-(6-aminohexyl) 
N-ethylamino]-2,3-dihydro-phthalaZine-1,4-dione or 6-[N 
(6-aminohexyl)-N-ethylamino] -2,3 -dihydro -phthalaZine-1 , 
4-dione. 
In another aspect of the present invention, a labeled probe 
is provided, comprising a peptide speci?c for a receptor, the 
peptide being derived from a bacteriophage or a synthetic 
analog or derivative of the peptide, and a marker. As described 
above, the marker is modi?ed to include a tether molecule 
capable of covalently binding to the peptide. The peptide is 
typically speci?c to a receptor on a bacterial cell Wall. The 
tether molecule may be capable of covalently binding to a 
primary amine of the peptide or to a carboxyl end of the 
peptide. Other features of the peptide, marker, and receptor 
are as described above. 
In yet another aspect, the present invention provides a 
method for detecting a bacterium in a complex mixture, com 
prising contacting the bacterium With a labeled probe as 
described above. The method is suited to a rapid assay tech 
nique for bacteria in a complex mixture, such as for example 
a milk or Whey preparation used in cheesemaking. 
As should be appreciated, the embodiments shoWn and 
described are an illustration of one of the modes best suited to 
carry out the invention. It Will be realiZed that the invention is 
capable of other different embodiments and its several details 
are capable of modi?cation in various, obvious aspects all 
Without departing from the invention. Accordingly, the draW 
ings and descriptions Will be regarded as illustrative in nature, 
and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The accompanying draWings incorporated in and forming 
a part of the speci?cation, illustrate several aspects of the 
present invention and together With the description serve to 
explain the principles of the invention. In the draWings: 
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FIG. 1 schematically depicts synthesis of a tether molecule 
on a luminol marker for covalently binding to a peptide; and 
FIGS. 2a and 2b schematically depict conjugation of a 
tri-lysine peptide (2a) and a Glu-Glu peptide (2b) to the 
compound of FIG. 1. 
Reference Will noW be made in detail to the present pre 
ferred embodiment of the invention, an example of Which is 
illustrated in the accompanying draWings. 
DETAILED DESCRIPTION OF THE INVENTION 
Methods of binding/ interaction betWeen many bacteria and 
bacteriophages are Well characteriZed. For example, the non 
pathogenic Laclococcus laclis ssp. laclis C2 host and <|>c2 
bacteriophage are one of the best characteriZed host/phage 
systems in the literature (Kraus, J . and B. L. Geller. 1998. 
Membrane Receptor for prolate phages is not required for 
infection of Laclococcus laclis by small or large isometric 
phages. J. Dairy Sci. 81:2329-2335; Lubbers, M. W., N. R. 
Water?eld, T. P. J . Beresford, R. W. F. LePage, and A. W. 
Jarvis. 1995. Sequencing and analysis of the prolate-headed 
lactococcal bacteriophage c2 genome and identi?cation of 
the structural genes. Appl. Environ. Microbiol. 6114348 
4356). In particular the peptides responsible for binding of 
many bacteriophages to bacteria have been isolated, charac 
teriZed, and sequenced. As an example, the binding protein in 
the membrane of the C2 host and its corresponding gene (pip) 
have been identi?ed (Kraus and Geller, 1998). This 99 kDa 
membrane protein contains the receptor con?guration that the 
<|>c2 phage binds to irreversibly. Also, the attachment protein 
(protein F) of the <|>c2 phage has been identi?ed and partially 
sequenced (Lubbers et al., 1995). Both the N-terminal and 
calcium binding sites of the <|>c2 phage F protein have been 
identi?ed (Lubbers et al., 1995). Thus, probes for rapid assay 
of bacteria in a mixture can be developed from viral sources 
by taking advantage of the speci?city of these attachment 
proteins, and more speci?cally of the peptides speci?cally 
responsible for binding. The present invention therefore pro 
vides bioactive probes comprising suchpeptides and a marker 
molecule. The peptide and marker are bound by a tether 
molecule, Which is important in distancing the marker from 
the peptide receptor to prevent steric hindrance of binding of 
subsequent bioactive probes and concomitant reduction in 
assay sensitivity. 
The folloWing examples are presented in support of and to 
further illustrate the invention as described above, but are not 
to be considered as limited thereto. 
EXAMPLE 1 
A process Was developed to prepare a site-speci?c probe, 
comprising modi?cation of a marker by addition of a tether 
molecule capable of covalently binding to a peptide. The 
peptide is desirably speci?c for a receptor on a surface of a 
target bacteria. The process is depicted schematically in FIG. 
1. In this experiment, the detectable molecule Was luminol 
(phthalic anhydride). Phthalic anhydride (11.7 g, 100 mmol) 
and 6-amino hexanol (14.8 g, 100 mmol) Were admixed With 
120 ml anhydrous toluene in a ?ask ?tted With Dean-Stork 
apparatus and re?uxed for 12 hr. at 1200 C. The Water formed 
Was removed as an aZeotrope. Toluene Was removed using 
rotavapor. A ?ash column chromatography Was performed 
over silica gel (230-400 mesh) With ethyl acetate and petro 
leum ether as eluant. The yield of the resulting 6-hydroxyl 
phthaliamide compound Was 22.7 g (92%), Mp 49-500 C. 
To 6-hydroxyl phthaliamide (22.5 g, 0.09 mole) in 100 ml 
of anhydrous toluene at 1100 C. Was added phosphorous 
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tribromide (17 g, 0.063 mole). The phosphorous tribromide 
Was taken in 20 ml of anhydrous toluene and added slowly 
through a pressure equalizing funnel. The mixture Was 
re?uxed for 3 hours and allowed to cool to room temperature. 
The orange precipitate formed Was removed by ?ltering 
through celite. The ?ltrate Was then concentrated in a rotavac 
to obtain an oil. The oil Was crystallized using absolute etha 
nol to yield 6-bromohexylphthalimide of analytical purity 
((25.1 g (90%), Mp 59-60° C.)). 
Next, 4-nitrophthalic acid (21.1 g, 0.1 mole) in a round 
bottomed ?ask Was admixed With acetic anhydride (40 ml) 
and re?uxed for 1 hour. The mixture Was brought to room 
temperature and acetic anhydride Was removed under 
vacuum. The concentrated mixture Was alloWed to stand over 
night, and the solid obtained Was recrystallized using toluene 
to give 4-nitrophthalic anhydride ((9.9 g (51%), Mp 119° 
C.)). 
The 4-nitrophthalic anhydride (9.5 g, 49.2 mmol) Was 
combined With 20 ml of 33% methylamine solution in abso 
lute ethanol in a round-bottomed ?ask and stirred for 2 hours 
at 0° C. The mixture Was acidi?ed to pH 2.0 With concentrated 
HCl, and concentrated under vacuum. The solid obtained Was 
re?uxed With 20 ml acetic anhydride for 15 min. and alloWed 
to stand overnight. The crystals obtained Were Washed With 
acetic acid, Water, and dried. Thin layer chromatography of 
the mother liquor indicated that a product Was present. The 
mother liquor Was evaporated, and the resulting slurry Was 
subjected to ?ash column chromatography over silica gel 
(240-300 mesh) With ethyl acetate and petroleum ether as 
eluant. Yield of N-methyl-4-nitrophthalimide Was 4.9 g 
(48%), Mp 177° C. 
To a solution of SnCl2 dihydrate (19.2 g, 85 mmol) in 8 ml 
Water and 24 ml concentrated Hcl Was added N-methyl-4 
nitrophthalimide (4.5 g, 21.8 mmol). The mixture Was stirred 
vigorously for 2 hours, and alloWed to stand overnight. The 
mixture Was then concentrated to 3/4 original volume using 
rotavapor. The solid obtained Was ?ltered and Washed With 
Water several times. The solid Was dried to give 4-amino-N 
methylphthalimide ((2.1 g (54.7%), Mp 247-248° C.). 
Next, to 6-bromohexylphthalimide (7.04 g, 22.7 mmol) in 
20 ml of anhydrous DMF under nitrogen atmosphere Was 
added 4-amino-N-methylphthalimide (4 g, 22.7 mmol). The 
mixture Was stirred under nitrogen at 120° C. for 30 hr. The 
reaction mixture Was then cooled to room temperature, placed 
in ice-cold Water and stirred. The resulting yelloW precipitate 
Was ?ltered and recrystallized from aqueous acetic acid. Yield 
of N-methyl-4-N- { 6-(N-phthalimidio)hexyl])aminophthal 
imide Was 4.5 g (49%), Mp 169-170° C. 
Next, N-methyl-4-N- {6-(N-phthalimidio)hexyl])ami 
nophthalimide (3.7 g, 9.2 mmol) Was admixed With diethyl 
sulfate (11 ml, 70.84 mmol) in a ?ask under nitrogen. This 
mixture Was gradually heated With stirring at 1 10° C. for 2 hr. 
The temperature Was then raised to 160° C. and kept for 20 
min. A broWn color developed. The mixture Was then cooled 
to room temperature, poured into ice cold Water, and stirred. 
The yelloW precipitate Was ?ltered and recrystallized from 
aqueous acetic acid. Yield of 4-[N-ethyl-N-(6-N-phthal 
imido)hexyl]amino-N-methyl phthalimide Was 2.3 g (58%), 
Mp 195-196° C. 
To 4-[N-ethyl-N-(6-N-phthalimido)hexyl]amino-N-me 
thyl phthalimide (1.75 g, 4.04 mmol) in 20 ml absolute etha 
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nol under nitrogen Was added hydrazine (5 ml, 147.1 mmol). 
The reaction mixture Was re?uxed for 3 hr under nitrogen. 
The solvent Was removed under vacuum, and the solid dried 
at 110° C. under vacuum. The residue Was dissolved in 10% 
HCl and ?ltered. The ?ltrate Was adjusted to pH 8 using 
potassium hydroxide. The resulting 6-[N-(6-aminohexyl)-N 
ethylamino] -2,3 -dihydro -phthalazine- 1 ,4-dione precipitate 
Was ?ltered and crystallized from aqueous dimethylforma 
mide (DMF). Yield Was 220 mg (18%). 
Finally, 6-[N-(6-aminohexyl)-N-ethylamino]-2,3-dihy 
dro-phthalazine-l,4-dione (608 mg, 2 mmol) in 10 ml anhy 
drous DMF under nitrogen Was admixed With diglycolic 
anhydride (232 mg, 2 mmol) and triethylamine (205 mg, 2 
mmol). The reaction mixture Was stirred under nitrogen for 
18 hr. The solvent Was removed under vacuum and the oil 
obtained Was dissolved in anhydrous methanol and kept at 4° 
C. for crystallization. Yield of 6-[carboxymethoxyacetyl-N 
(6-aminohexyl)-N-ethylamino] -2,3 -dihydro -phthalazine-1 , 
4-dione Was 420 mg (50%). This product is then reacted With 
the primary amine of a peptide derived from a bacteriophage, 
or a synthetic analog or derivative of the peptide, to form a 
?uorescently labeled peptide speci?c to the receptor of 
choice. If it is desired to bind the marker to the carboxyl end 
of the peptide, then the 6-[N-(6-aminohexyl)-N-ethylamino] - 
2,3-dihydro-phthalazine-1,4-dione is reacted With the pep 
tide. The marker includes a 6 carbon tether molecule, Which 
binds to the peptide, thereby providing a distance betWeen the 
marker and the peptide When the peptide binds to a receptor 
on a bacterial cell surface. 
EXAMPLE 2 
To standardize the reaction conditions, the isoluminol 
marker synthesized as described in Example 1 Was coupled 
With loW molecular Weight synthesized peptides. TWo pep 
tides, Lys-Lys-Lys and Glu-Glu Were selected. The tri-lysine 
peptide Was selected due to the availability of several amine 
attachment sites. Glu-Glu Was selected due to its carboxyl 
sites. Both peptides Were reacted With the reporter molecule 
6-[carboxymethoxyacetyl-N-(6-aminohexyl)-N-ethy 
lamino]-2,3-dihydro-phthalazine-1,4-dione, prepared as 
described in Example 1. Puri?ed probes Were tested using 
mass spectrometry (Maldi method) and proton and carbon 
nuclear magnetic resonance (N MR). 
As depicted schematically in FIG. 2, the tri-lysine peptide 
Was reacted With 6-[carboxymethoxyacetyl-N-(6-amino 
hexyl)-N-ethylamino] -2,3 -dihydro -phthalazine- 1 ,4-dione in 
the presence of dicyclohexylcarbodiimide (DCC) and anhy 
drous methanol at ambient temperature under nitrogen. NMR 
spectra shoWed that the resulting probe Was a single posi 
tional isomer. Mass spectrometry indicated that the monomer 
had a molecular Weight of 805, corresponding to the molecu 
lar ion of the monoconjugated product. A small amount of 
tri-lysine reacted With tWo reporter molecules (less than 
0.5%), and had a molecular Weight of 1208. Although not 
Wishing to be bound to any particular theory, because a single 
positional isomer Was formed the reaction betWeen the tri 
lysine and the reporter molecule may have occurred betWeen 
the peptide primary amine and the terminal carboxyl group of 
the reporter. lmportantly, successful binding of the tri-lysine 
peptide to the reporter indicated that blockers on the e-amine 
Were unnecessary to produce the desired bioactive probe. 
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EXAMPLE 3 
The glu-glu peptide Was reacted With 6-[carboxymethoxy 
acetyl-N-(6-aminohexyl)-N-ethylamino]-2,3-dihydro-ph 
Ox 
Ala-Lys-Glu-Lys-Tyr-Val-lle-Gln-Ala-Glu-Lue-Glu + 
Amino acid sequence HO 
O 
H 
thalaZine-l,4-dione in the presence of dicyclohexylcarbodi 
imide (DCC), anhydrous methanol, and a feW drops of DMF 
at 75-80° C. NMR spectra showed that the resulting probe 
Was a single positional isomer. Mass spectrometry indicated 
that the methylated monomer had a molecular Weight of 707. 
Although not Wishing to be bound to any particular theory, 
because a single positional isomer Was formed, the reaction 
betWeen the Glu-Glu peptide and the reporter molecule may 
have occurred betWeen the primary amine and the terminal 
carboxyl group of the probe. 
The Glu-Glu peptide is knoWn to be a potent inhibitor of 
groWth forL. laclis ssp. laclis C2 and other lactic acid bacteria 
having calcium binding receptors on their outer membrane. 
Accordingly, the bioactive Glu-Glu probe synthesized herein 
is expected to bind Well to all gram positive bacteria having 
calcium binding receptors. 
EXAMPLE 4 
The Glu-Glu probe of Example 3 Was produced, With the 
exception that the coupling reaction Was carried out in anhy 
drous DMF Without methanol to prevent formation of the 
dimethyl ester of the coupled monoconjugated product. 
EXAMPLE 5 
Abio-active probe highly speci?c to Laclococcus laclis ssp 
laclis C2 Was provided. The N-terminal sequence of amino 
acids from the c2 phage F protein are highly speci?c to the 
receptors on the outer membrane of L. Laclis ssp laclis C2. 
Thus, by combining the N-terminal sequence of amino acids 
from the c2 phage F protein to the marker produced as 
described in Example 1, the probe is highly speci?c for the C2 
laclis strain. The speci?c amino acid sequence can be derived 
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from the F protein, from a genetically engineered source, or 
synthesized commercially. The primary amine of Glu Was 
then covalently bound to the carboxyl end of the tethered 
reporter molecule as shoWn beloW. 
K o H 
\ /\/\/\/N 
“W oil“ / NH 0 
o 
6[Carboxymethoxyacetyl-N-ethylarnino] 
—2 ,3 -dihydro-Phthalazine— l ,4 dione 
K H 
NH 
O 
The bio-active probe produced by this procedure Was 
added in excess to C2 bacteria at concentrations of 102, 103, 
and 104 cfu/ml. The bio-active probe Was then alloWed to 
absorb onto the surface of the C2 bacteria for 20 min. The 
bacteria Were spun doWn (5000><g for 10 min), the pellet Was 
suspended and Washed With phosphate dilution buffer, spun 
doWn again, and Washed a second time as before. The pellet 
Was suspended in phosphate buffer and ?uorescence from the 
bio-active reporter molecule Was determined using a GENios 
PlusTM, a multi-detection microplate reader. The folloWing 
data Were collected from the reader using an appropriate 
blank. 
Concentration of C2 bacteria Fluorescence 
104 c?J/ml 0.114 
103 c?J/ml 0.072 
102 c?J/ml 0.058 
This suggests that bacteria in concentrations as loW as 102 
cfu/ml could be determined using this method. 
The foregoing description of the preferred embodiment of 
this invention has been presented for purposes of illustration 
and description. It is not intended to be exhaustive or to limit 
the invention to the precise form disclosed. Obvious modi? 
cations or variations are possible in light of the above teach 
ings. The embodiment Was chosen and described to provide 
the best illustration of the principles of the invention and its 
practical application to thereby enable one of ordinary skill in 
the art to utiliZe the invention in various embodiments and 
With various modi?cations as are suited to the particular use 
contemplated. All such modi?cations and variations are 
Within the scope of the invention as determined by the 
appended claims When interpreted in accordance With the 
breadth to Which they are fairly, legally, and equitably 
entitled. 
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SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 4 
TYPE: PRT 
ORGANISM: c2 bacteriophage 
<400> SEQUENCE: 1 
Ala Glu Leu Glu 
l 
SEQ ID NO 2 
LENGTH: 5 
TYPE: PRT 
ORGANISM: c2 bacteriophage 
<400> SEQUENCE: 2 
Ser Asn Glu Glu Met 
1 5 
SEQ ID NO 3 
LENGTH: 12 
TYPE: PRT 
ORGANISM: c2 bacteriophage 
<400> SEQUENCE: 3 
Ala Lys Glu Lys Tyr Val Ile Gln Ala Glu Leu Glu 
l 5 10 
What is claimed is: 
1. A method for preparing a site-speci?c peptide probe, 
Wherein the peptide is speci?c to a receptor, comprising: 
modifying a 6-[N-(6-aminohexyl)-N-ethylamino]-2,3-di 
hydro-phthalaZine-l,4-dione marker to include an 
amino-terminal carboxymethoxyacetyl tether molecule; 
and 
covalently binding the tether molecule to a bacteriophage 
derived peptide or synthetic peptide Which binds a bac 
terial surface receptor therefor. 
2. The method of claim 1, Wherein the receptor is the 
bacteriophage F protein receptor. 
3. The method of claim 2, Wherein the peptide consists of 
Ala-Glu-Leu-Glu (SEQ ID NO: 1), Ser-Asn-Glu-Glu-Met 
(SEQ ID NO: 2), Ala-Lys-Glu-Lys-Tyr-Val-Ile-Gln-Ala-Glu 
Leu-Glu (SEQ ID NO: 3), Lys-Lys-Lys, or Glu-Glu. 
4. The method of claim 2, Wherein the bacteriophage is 
selected from the group of bacteriophages speci?cally bind 
ing to Laclobacillus, Laclococcus, Salmonella, Escherichia, 
and mixtures thereof. 
5. The method of claim 4, Wherein the bacteriophage is 
selected from the group of bacteriophages speci?cally bind 
ing to Laclobacillus planlarum species, Laclococcus lacZis 
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species, Salmonella Zyphimurium species, Salmonella chol 
eraesuis species, Escherichia coli species, and mixtures 
thereof. 
6. The method of claim 5, Wherein the bacteria is Lacto 
coccus lacZis ssp. lacZis C2. 
7. A method for preparing a site-speci?c peptide probe, 
Wherein the peptide is speci?c to a receptor, comprising: 
modifying a 6-[N-(6-aminohexyl)-N-ethylamino]-2,3-di 
hydro-phthalaZine-l ,4-dione marker to include an 
amino-terminal carboxymethoxyacetyl tether molecule; 
and 
covalently binding the tether molecule to a bacteriophage 
derived peptide Which binds a bacterial surface receptor 
for a bacteriophage F protein. 
8. The method of claim 7, Wherein the peptide consists of 
Ala-Glu-Leu-Glu (SEQ ID NO: 1), Ser-Asn-Glu-Glu-Met 
(SEQ ID NO: 2), Ala-Lys-Glu-Lys-Tyr-Val-Ile-Gln-Ala-Glu 
Leu-Glu (SEQ ID NO: 3), Lys-Lys-Lys, or Glu-Glu. 
9. The method of claim 7, Wherein the bacteriophage is 
selected from the group of bacteriophages speci?cally bind 
ing to Laclobacillus, Laclococcus, Salmonella, Escherichia, 
and mixtures thereof. 
10. The method of claim 9, Wherein the bacteriophage is 
selected from the group of bacteriophages speci?cally bind 
ing to Laclobacillus planlarum species, Laclococcus lacZis 
US 7,759,468 B1 
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species, Salmonella zyphimurium species, Salmonella chal- covalently binding the tether molecule to a bacteriophage 
eraesuis species, Escherichia coli species, and mixtures derived peptide or Synthetic peptide which binds a bac 
thereof. 
11. The method of claim 10, Wherein the bacteria is Lac 
lococcus laclis ssp. laclis C2. 
12. A method for preparing a site-speci?c peptide probe, 
terial surface receptor therefor; 
5 Wherein the bacteriophage-derived peptide or synthetic 
peptide is selected from the group consisting ofAla-Glu 
Wherein the peptide is speci?c to a receptor, comprising: Leu'Glu (SEQ ID NO? 1), Ser-ASn-Glu-Glu-Met (SEQ 
modifying a 6-[N-(6-aminohexyl)-N-ethylamino]-2,3-di- ID N01 2), Ala-Lys‘G111'Lys'Tyr-Val-He-Gln-Ala-Glu' 
hydro-phthalaZine-l,4-dione marker to include an 10 Leu-Glu (SEQ ID N01 3), LYS'LYS'LYS, 0r Glu-Glu 
amino-terminal carboxymethoxyacetyl tether molecule; 
and * * * * * 
